Johnson & Johnson Navigates Cardiovascular Growth Headwinds as Abiomed Impella Safety Concerns Pressure MedTech Earnings
Johnson & Johnson (J&J) reported a complex second quarter for its MedTech division, characterized by a significant deceleration in its…
